Lv4
428 积分 2024-09-27 加入
A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease
1天前
待确认
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
1个月前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
1个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
1个月前
已完结
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
1个月前
已完结
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
1个月前
已完结
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
2个月前
已完结
Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study
2个月前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
2个月前
已完结
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
2个月前
已完结
皖公网安备34019202002308
